This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Mar 2011

Ambrilia & ZBx Ink Licensing Deal

Ambrilia and ZBx has entered into an exclusive license option agreement for the worldwide rights to Ambrilia's PSP-94 technology for prostate cancer diagnosis.

Ambrilia Biopharma has reached an agreement granting ZBx Corp. an option to acquire exclusive worldwide rights to Ambrilia's PSP-94 reagents and related intellectual property.

 

If ZBx exercises its option, Ambrilia would be eligible to receive as much as $50,000 upfront, sales milestones, royalties on sales, as well as a percentage of proceeds from any sublicenses or sale of PSP-94. ZBx will cover further development, manufacturing and commercialization costs.

Related News